Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Enyo Pharma SAS

www.enyopharma.com

Latest From Enyo Pharma SAS

Record Breaking First Half For Start-Ups Raising Cash In Europe

The first half of 2018 appeared promising for the European biopharma sector, with multiple large investment funds promising cash to young, innovative companies in the region – a turnaround after years of life science firms suffering from a funding drought across Europe.

Growth Financing

Venture Funding Deals: I-Mab Is The Mega-Round Leader With $220m Series C

Freeline Therapeutics, I-Mab Biopharma, Kaleido Biosciences and Precision BioSciences raised more than $100m each, but Chinese start-ups continue to bring in some of this year's largest venture capital mega rounds, with $220m in Series C cash to fund development of immuno-oncology and inflammatory disease drug candidates.

Financing StartUps and SMEs

Learning From Human Cell Hijacking Masters: ENYO Pharma Takes Virus Tricks Into Drug Discovery

Emerging Company Profile: ENYO Pharma has been around for barely four years, but it is already advancing its lead programs into Phase II trials in hepatitis B and NASH, and anticipates many more uses for its virology-based platform that will go way beyond treating virus infections.

StartUps and SMEs Platform Technologies

Finance Watch: Pfizer Ventures' Dalton Makes Sense Of Neuroscience Focus Within New $600m VC Fund Commitment

Venture Capital Edition: Pfizer deprioritized neuroscience as an early R&D focus earlier this year, but will stay involved by spending 25% of the $600m added to its venture fund on neurology investments. Also, China VC investment keeps up fast pace and Alta Partners closes a new $130m health care fund.

Financing StartUps and SMEs
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
    • Large Molecule
  • Pharmaceuticals
  • Therapeutic Areas
  • Hepatic (Liver)
  • Infectious & Viral Diseases
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • France
  • Parent & Subsidiaries
  • Enyo Pharma SAS
  • Senior Management
  • Jacky Vonderscher, PhD, CEO
    Pascale Boissel, CFO
    Eric Meldrum, PhD, CSO
    Nicolas Guyon-Gellin, MD, VP, Corp. Dev. & Strategy
    Pietro Scalfaro, MD, CMO
  • Contact Info
  • Enyo Pharma SAS
    321 avenue Jean Jaurès
    Lyon, 69007
    France
Advertisement
Advertisement
UsernamePublicRestriction

Register